IRIS
BERSANELLI, MELISSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.938
NA - Nord America 3.832
EU - Europa 2.266
SA - Sud America 854
AF - Africa 268
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 11.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.726
SG - Singapore 1.725
CN - Cina 678
VN - Vietnam 656
BR - Brasile 646
IE - Irlanda 586
SE - Svezia 454
HK - Hong Kong 362
IT - Italia 252
FR - Francia 194
DE - Germania 180
ZA - Sudafrica 176
NL - Olanda 148
AT - Austria 115
FI - Finlandia 81
AR - Argentina 73
IN - India 72
BD - Bangladesh 62
RU - Federazione Russa 62
GB - Regno Unito 55
IR - Iran 46
TR - Turchia 45
CA - Canada 44
IQ - Iraq 44
ID - Indonesia 42
EC - Ecuador 36
MX - Messico 35
CO - Colombia 28
BE - Belgio 24
JP - Giappone 24
VE - Venezuela 22
PH - Filippine 20
PK - Pakistan 20
MA - Marocco 19
UZ - Uzbekistan 19
CZ - Repubblica Ceca 18
PL - Polonia 18
PY - Paraguay 18
KR - Corea 16
UA - Ucraina 15
CI - Costa d'Avorio 13
EG - Egitto 13
ES - Italia 12
KE - Kenya 12
LT - Lituania 11
MY - Malesia 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
KZ - Kazakistan 9
SA - Arabia Saudita 9
TW - Taiwan 9
DO - Repubblica Dominicana 8
JO - Giordania 8
TH - Thailandia 8
BO - Bolivia 7
NP - Nepal 7
PE - Perù 7
TN - Tunisia 7
UY - Uruguay 7
EE - Estonia 6
BG - Bulgaria 5
ET - Etiopia 5
OM - Oman 5
PA - Panama 5
SN - Senegal 5
AL - Albania 4
AO - Angola 4
AZ - Azerbaigian 4
DZ - Algeria 4
KW - Kuwait 4
PS - Palestinian Territory 4
RO - Romania 4
RS - Serbia 4
BH - Bahrain 3
CR - Costa Rica 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
NG - Nigeria 3
QA - Qatar 3
AU - Australia 2
CH - Svizzera 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
JM - Giamaica 2
MD - Moldavia 2
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BT - Bhutan 1
BY - Bielorussia 1
CD - Congo 1
CV - Capo Verde 1
CY - Cipro 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
Totale 11.143
Salva come PNG Salva come JPEG
Città #
Singapore 819
Dublin 580
Ashburn 577
Chandler 462
San Jose 453
Hong Kong 354
Santa Clara 316
Ho Chi Minh City 211
Boardman 179
Beijing 164
Dallas 164
Johannesburg 156
Hanoi 150
Lauterbourg 123
Princeton 113
Vienna 109
Shanghai 105
Ann Arbor 79
New York 71
Los Angeles 69
Munich 69
São Paulo 62
Helsinki 55
Council Bluffs 53
Tehran 38
Frankfurt am Main 31
Parma 31
Rio de Janeiro 31
Columbus 30
Moscow 30
Bremen 28
Milan 26
Wilmington 26
Da Nang 25
Des Moines 25
Turku 25
Chicago 24
The Dalles 24
Jakarta 23
Bologna 22
Brussels 22
Haiphong 22
Nuremberg 21
Buffalo 20
Belo Horizonte 18
Orem 18
Guangzhou 16
Guayaquil 16
London 16
Phoenix 15
Seattle 15
Stockholm 15
Tashkent 15
Atlanta 14
Baghdad 14
Brasília 14
Hefei 14
Tianjin 14
Warsaw 14
Abidjan 13
Boston 13
Brooklyn 13
Chennai 13
Tokyo 13
Curitiba 12
Dearborn 12
Montreal 12
Quito 12
Rome 12
Toronto 12
Houston 11
Hải Dương 11
Asunción 10
Düsseldorf 10
Marseille 10
Nanjing 10
Brno 9
Denver 9
Lahore 9
Medellín 9
Nairobi 9
Ankara 8
Biên Hòa 8
Dhaka 8
Poplar 8
Pune 8
Sorocaba 8
Verona 8
Borås 7
Buenos Aires 7
Bắc Ninh 7
Fortaleza 7
Fremont 7
Izmir 7
Montevideo 7
Olomouc 7
Rio Saliceto 7
San Francisco 7
Seoul 7
Amman 6
Totale 6.628
Salva come PNG Salva come JPEG
Nome #
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 202
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 189
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 180
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 161
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 152
Review on radiological evolution of COVID-19 pneumonia using computed tomography 150
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 144
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 142
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 141
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 137
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 137
Asymptomatic pulmonary embolism in lung cancer: Prevalence and analysis of clinical and radiological characteristics in 141 outpatients 136
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 135
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 133
Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer 132
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 130
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 125
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 124
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 122
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 118
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 117
Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma 115
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 113
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 111
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 111
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 111
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 109
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 108
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 107
Avelumab Maintenance for Urothelial Carcinoma 106
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 105
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 104
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 104
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 103
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 102
The effect of COVID-19 emergency in the management of melanoma in Italy 101
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 101
Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients 100
Renal cell carcinoma and viral infections: A dangerous relationship? 99
Cabozantinib in RCC: only a METEOR or a rising star? 98
Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? 98
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 96
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 94
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 94
Patient performance status and cancer immunotherapy efficacy: a meta-analysis 94
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 94
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 93
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study 93
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 92
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 91
Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma 91
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 90
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27 90
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 89
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 88
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 87
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients 86
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series 86
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 85
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study 84
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 83
The 'nivolution' in renal cell carcinoma: Behind the scenes of clinical trials 83
The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma 83
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 82
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients 81
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak 80
Capter 4 - Adjuvant Therapy for Renal Cell Carcinoma 79
Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: Evidence to date 78
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 76
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 76
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 74
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 74
Reassessing Human Adipose Tissue 74
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review 72
Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis 72
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 70
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 70
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 70
Corrigendum: Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: The GRANT score applied to the ASSURE trial population [Ann Oncol., 28, (2017) (2747-2753)] DOI: 10.1093/annonc/mdx492 70
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 70
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis 69
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 69
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 68
Pathological nodal staging score for renal cell carcinoma: How to build reliable therapeutic choices basing on assumptions 68
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A transversal challenge. the INVIDIa study 67
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup 67
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: Preliminary report of the FAMI-L1 study 66
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 65
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 65
Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next? 65
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 65
Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials 64
Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients 64
Pazopanib in renal cell carcinoma dialysis patients: A mini-review and a case report 63
State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough 60
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 58
Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: A pooled analysis of 926 patients 58
Systemic adjuvant therapies in renal cell carcinoma 57
Totale 9.802
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.212
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202147 0 0 0 0 0 0 0 0 0 19 10 18
2021/2022541 11 14 13 24 6 3 160 45 28 6 40 191
2022/20231.984 239 222 118 123 146 224 12 99 691 13 71 26
2023/2024743 39 64 21 20 61 152 52 45 32 44 86 127
2024/20252.642 38 154 195 111 226 351 128 120 263 346 199 511
2025/20265.108 472 476 638 601 846 248 550 171 672 434 0 0
Totale 11.367